The abstract is read at the publisher; the summary is JClub's.
In a US observational cohort of 237 adults with obesity on weekly semaglutide or tirzepatide, daily food noise prevalence ranged from 4.3% to 23.8% and peaked on dosing day.
- Why it matters: Weekly GLP-1 trials often miss day-to-day fluctuations in food-related experiences between scheduled visits, limiting understanding of how symptoms vary across the dosing interval.
- What they did: Adults with BMI ≥ 30 kg/m2 completed daily 24-hour-recall electronic diaries for 6 weeks while each injection defined Day 1, tracking food noise, cravings, hunger, satiety, and fullness.
- The result: Food noise generally declined after dosing and returned toward dosing-day levels by Day 7, suggesting daily assessments can reveal patterns not captured by conventional trial schedules.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.